Recardio at LSX World Congress USA
- Sep 15, 2025
- 1 min read
Updated: May 26
San Francisco, September 15, 2025 - Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular diseases, announced today that it is participating in the LSX World Congress USA in Boston.
The congress gathers leaders from the US Biotech, Medtech, and Pharmatech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology.
The event is taking place on September 16-17, 2025 in Boston.
Recardio will be participating and presenting its technology and clinical therapy program for cardiovascular diseases.
About Recardio
Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.
The company is located in San Francisco, California, with operations in the USA and Europe.
Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.
In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.
For more information, visit: www.recardio.eu or contact pr@recardio.eu
